Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 10Squamous Cell Carcinoma of Head and Neck 6Stomach Neoplasms 4Prostatic Neoplasms 4Neoplasms 4Lung Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Oropharyngeal Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Cholangiocarcinoma 3Breast Neoplasms 3Weight Loss 2Uterine Cervical Neoplasms 2Recurrence 2Myasthenia Gravis 2Mouth Neoplasms 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma 2

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Autistic Disorder × 30 days × Clear all
NCT07218575 2026-06-04

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

Boston Children's Hospital

Phase 2/3 Not yet recruiting
60 enrolled

Autistic Disorder, Hamartoma Syndrome, Multiple

Data powered by HemOnc (CC BY 4.0) Colophon âš¡